Physician profile
Lee Spain
NPI 1427281559
$42,226.46
in general payments reported to CMS, 2019-2025
34 companies · $3,648 in 2025
The $3,648 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,671 · 2021: $5,531 · 2022: $12K · 2023: $1,909 · 2024: $2,577 · 2025: $3,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,712 · Education: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,712.11 |
| Education | $422.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $26,652.24 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $3,196.51 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,991.30 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,559.01 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,011.49 | 2019-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $959.61 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $888.44 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $784.43 | 2019-2025 | Trintellix |
| Abbvie INC. | $564.09 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $526.46 | 2019-2023 | Belsomra |
| Axsome Therapeutics, INC. | $502.33 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $494.33 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $418.07 | 2022-2025 | Azstarys |
| Allergan, INC. | $409.88 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $353.66 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $314.86 | 2024-2025 | Cobenfy |
| Eisai INC. | $227.60 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $217.15 | 2019 | |
| Sage Therapeutics, LLC | $198.05 | 2024-2025 | Zurzuvae |
| Avanir Pharmaceuticals, INC. | $186.40 | 2019-2022 | |
| Indivior INC. | $145.63 | 2019-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $116.81 | 2021-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $101.73 | 2022-2025 | Wegovy, Saxenda |
| Jazz Pharmaceuticals INC. | $100.04 | 2019 | |
| Shire North American Group INC | $65.61 | 2019 | |
| Tris Pharma INC | $51.27 | 2021-2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $39.82 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $30.19 | 2023-2024 | Quviviq |
| Boston Scientific Corporation | $23.80 | 2025 | Watchman Flx |
| Noven Therapeutics, LLC | $22.52 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $21.16 | 2023 | Adzenys Xr-Odt |
| Sun Pharmaceutical Industries INC. | $20.06 | 2021 | |
| Neuronetics, INC. | $18.11 | 2019 | |
| Bioxcel Therapeutics, INC. | $13.80 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Spain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.